Oxford Genetics Ltd
Registered name: OXFORD GENETICS LTD
Part of Avant UK Buyer Limited groupOxford Genetics Ltd made £2.6m revenue and a £6.1m loss in the year to 31 Dec 2024.
Oxford Genetics Ltd’s revenue fell 72% to £2.6m in the year to 31 Dec 2024, with a loss of £6.1m and 57 employees. The company is classified under “research and experimental development on biotechnology” and is based in London; we hold 3 years of its filed accounts.
- Status
- Active
- Location
- London, London
- Age
- 15 yrs · since 2011
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 |
|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L |
| Profit & loss | |||
| Revenue (turnover) | £14m | £9.1m | £2.6m |
| Cost of sales | £2.2m | £1.7m | £676k |
| Gross profit | £11.9m | £7.5m | £1.9m |
| Operating profit | −£580k | −£2.4m | −£5.4m |
| Profit before tax | −£857k | −£3.5m | −£6.1m |
| Profit after tax | −£1m | −£3.6m | −£6.1m |
| Profit (best available) | −£1m | −£3.6m | −£6.1m |
| Staff costs | £7m | £5.3m | £3.6m |
| Employees (average) | 123 | 103 | 57 |
| Ratios | |||
| Profit margin | −7.2% | −39.5% | −236.8% |
| Gross margin | 84.5% | 81.7% | 73.8% |
| Revenue per employee | £114k | £88.7k | £45.2k |
| Profit per employee | −£8.2k | −£35k | −£107k |
| Growth (year on year) | |||
| Revenue growth | — | ▼34.9% | ▼71.8% |
| Headcount growth | — | ▼16.3% | ▼44.7% |
| Balance sheet — indirect signals, not revenue | |||
| Cash at bank | £3.8m | £2.3m | £1.1m |
| Net assets | −£3.2m | −£7m | −£13.1m |
| Debtors | £277k | £1.3m | £106k |
| Deferred income | £1.1m | £1.9m | £748k |
| Source | FullAccounts · bulk data Jun 2024 | FullAccounts · bulk data Jun 2024 | FullAccounts · bulk data Oct 2025 |
How the business works
- Profit margin
- −236.8%
- Profit ÷ revenue.
- Gross margin
- 73.8%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £45.2k
- Revenue ÷ average employees.
- Profit per employee
- −£107k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 29%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 4.1%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now −£13.1m
- Cash at bank
- ▼51%
- Now £1.1m
- Headcount
- ▼45%
- Now 57
- Deferred income
- ▼60%
- Now £748k
- Fixed assets
- —
- Now —
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Group structure
Ownership chain
- Avant UK Buyer Limitedultimate parent75–100%
- Oxford Genetics Ltdthis company
Bands show the share of ownership each company holds in the one below it.
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Takara Bio UK LtdLondon · Research and experimental development on biotechnology
- Revenue
- £3.1m
- Profit
- £97.2k
- Staff
- 9
- Clinicology Ltd.Guildford · Research and experimental development on biotechnology
- Revenue
- £1.4m
- Profit
- £79.1k
- Staff
- 7
- Adorx Therapeutics LimitedEdinburgh · Research and experimental development on biotechnology
- Revenue
- £1.2m
- Profit
- £211k
- Staff
- 0
- Nuritas UK LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £1.2m
- Profit
- £88.8k
- Staff
- 4
- Clinuvel (UK) LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £6.4m
- Profit
- £81.6k
- Staff
- 46
Sources
Latest figures from FullAccounts for the year to 31 Dec 2024 (profit −£6.1m), from the Companies House accounts bulk data published Oct 2025. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.